(19)
(11) EP 3 952 923 A1

(12)

(43) Date of publication:
16.02.2022 Bulletin 2022/07

(21) Application number: 20787456.1

(22) Date of filing: 10.04.2020
(51) International Patent Classification (IPC): 
A61K 48/00(2006.01)
A61K 38/00(2006.01)
C07H 21/04(2006.01)
C12N 15/11(2006.01)
C12N 15/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/00; A61K 9/0085; A01K 2227/105; A01K 2207/20; A01K 2267/0318; C12N 2750/14143; C12N 15/86; A61K 48/005; A61K 9/0019; C12N 2310/14; C12N 2320/31; C12N 2330/51; C12N 15/113; C12Y 302/01045; C12N 9/2402; C07K 14/475; C07K 14/705
(86) International application number:
PCT/US2020/027658
(87) International publication number:
WO 2020/210615 (15.10.2020 Gazette 2020/42)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 10.04.2019 US 201962831856 P
10.04.2019 US 201962831840 P
10.04.2019 US 201962831846 P
10.04.2019 US 201962832223 P
12.11.2019 US 201962934450 P
27.12.2019 US 201962954089 P
13.01.2020 US 202062960471 P
12.03.2020 US 202062998665 P
16.03.2020 US 202062990246 P

(71) Applicant: Prevail Therapeutics, Inc.
New York, NY 10016 (US)

(72) Inventors:
  • ABELIOVICH, Asa
    New York, NY 10016 (US)
  • HECKMAN, Laura
    New York, NY 10016 (US)
  • RHINN, Herve
    New York, NY 10016 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) GENE THERAPIES FOR LYSOSOMAL DISORDERS